G7 Cancer is an international cooperation mechanism that brings together the most advanced countries in the fight against cancer. It provides a unique forum for participating organizations to share expertise, improve knowledge of cancer mechanisms, accelerate the transfer of scientific discoveries and their clinical application, and stimulate innovation on an international scale.
At the initiative of the French National Cancer Institute (INCa), G7 Cancer officially launched on May 9, 2023, bringing together these organizations:
AUSTRALIA
CANADA
FRANCE
GERMANY
JAPAN
UNITED KINGDOM
UNITED STATES
WORLD HEALTH ORGANIZATION
Four working groups were gradually set up in order to address the main priorities of the G7 Cancer:
WG1 – International data strategy, focused on pediatric cancers as a model.
WG2 – Poor prognosis cancers (pancreatic/esophagus/stomach and liver cancers).
WG3 – Cancer outcome inequities.
WG4 – Prevention (precancers, screening programs, multi-cancer early detection).
non-governmental, international).
2. G7 Cancer is open to other organizations and membership granted based on the mutual consent of Participant organizations.
3. G7 Cancer deals primarily with complex topics needing international cooperation and especially with blind spots.
4. The secretariat and presidency will be established on a rotating basis.
5. Activities will be financed on a program-by-program basis.
6. G7 Cancer builds on what already exists, particularly on the strategies and programs of the Participant organizations.